Synonymous mutation frequencies and survival rates at imposed values of μ and λ are in conflict with traditional models of eukaryotic evolution and constraint. by Zackery E. Plyler (18570572)

Ultraflexible Oxide Fibers with an Amorphous Silica Interfacial Layer on Zirconia Nanograins by Dehua Ma (500180)

Ultraflexible Oxide Fibers with an Amorphous Silica Interfacial Layer on Zirconia Nanograins by Dehua Ma (500180)

Ultraflexible Oxide Fibers with an Amorphous Silica Interfacial Layer on Zirconia Nanograins by Dehua Ma (500180)

Ultraflexible Oxide Fibers with an Amorphous Silica Interfacial Layer on Zirconia Nanograins by Dehua Ma (500180)

Ultraflexible Oxide Fibers with an Amorphous Silica Interfacial Layer on Zirconia Nanograins by Dehua Ma (500180)

Population analysis of boundary vector cells. by Lear Cohen (15353793)

Risk of bias of the included studies. by Lin Wang (11986)

“…ID=CRD42023390972" target="_blank">CRD42023390972</a>.</p></div>…”

Summary of details of the included studies. by Lin Wang (11986)

“…ID=CRD42023390972" target="_blank">CRD42023390972</a>.</p></div>…”

Silanization of 3D-Printed Silica Fibers and Monoliths by David Vogelsang (12890151)

“…As the interfiber distance of the monolith decreases, a significantly lower density of amine groups is detected in the core of the monolith. …”

Biopsy. by Julia María Cabo del Riego (21703071)

“…Increasing CD incidence was observed from 13.11 per 100.000 person/year in 2012 to 20.92 per 100.000 100.000 person/year in 2019 (95% CI = 6.8–15.5). The temporal trend in incidence rates diverges between different age groups; showing a high incidence with stable pattern in children and young people whereas exhibiting an increasing incidence in adult/elderly, so that the incidence almost triple from 2012 to 2019. …”

CD diagnosis method. by Julia María Cabo del Riego (21703071)

“…Increasing CD incidence was observed from 13.11 per 100.000 person/year in 2012 to 20.92 per 100.000 100.000 person/year in 2019 (95% CI = 6.8–15.5). The temporal trend in incidence rates diverges between different age groups; showing a high incidence with stable pattern in children and young people whereas exhibiting an increasing incidence in adult/elderly, so that the incidence almost triple from 2012 to 2019. …”

Estimated prevalence of delayed ART initiation. by Yan Tao (299924)

“…The overall pooled prevalence of delayed ART initiation was 36.1% [95% confidence interval (CI), 29.7–42.5%]. In subgroup analysis, the estimated pooled prevalence decreased with age. …”

Sensitivity analysis. by Yan Tao (299924)

“…The overall pooled prevalence of delayed ART initiation was 36.1% [95% confidence interval (CI), 29.7–42.5%]. In subgroup analysis, the estimated pooled prevalence decreased with age. …”

Natural disease history of the <i>dy^2J</i> mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy by S. Pasteuning-Vuhman (4348486)

“…<div><p>Merosin deficient congenital muscular dystrophy 1A (MDC1A) is a very rare autosomal recessive disorder caused by mutations in the <i>LAMA2</i> gene leading to severe and progressive muscle weakness and atrophy. …”

Parasitological parameters of infected <i>EBi3</i>^<i>-/-</i> and WT mice. by Ester Alves Mota (8474316)

Controlling the Temperature and Speed of the Phase Transition of VO₂ Microcrystals by Joonseok Yoon (1419355)

Risk of bias across 22 included studie. by Kuo-Chuan Hung (8587392)

“…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”

An overview of the selection process for studies. by Kuo-Chuan Hung (8587392)

“…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”

Characteristics of studies (<i>n</i> = 22). by Kuo-Chuan Hung (8587392)

“…Trial sequential analysis (TSA) was conducted to validate the reliability.</p><p>Results</p><p>A meta-analysis of 22 RCTs (n = 3,463) showed that ketamine/esketamine significantly decreased PPD risk at 1- (risk ratio [RR], 0.41; 95% confidence interval [CI], 0.3–0.57) and 4–6-week (RR, 0.47; 95%CI, 0.35–0.63) follow-ups. …”